Clostridium difficile–Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A formerly infrequently isolated strain of Clostridium difficile known as BI/NAP1 has resulted in geographically diverse outbreaks of C. difficile – associated disease. Such rapid dissemination and distribution of an outbreak strain of C. difficile are unprecedented, with many regions across North America, as well as several countries in Europe, being affected, all in such a short period of time. Also of note is that nontraditional hosts (e.g., otherwise healthy, noninstitutionalized persons residing in the community, some without antimicrobial exposure) have been reported to have severe disease. Data suggest that certain virulence characteristics may be responsible for more severe clinical presentations and poor outcomes. These factors (e.g., hypertoxin production, hypersporulation, antimicrobial resistance) possessed by a previously uncommon strain of C. difficile , in conjunction with particular host and environmental factors, may have precipitated the now widespread establishment of this pathogen. Antimicrobial intervention has traditionally been a mainstay of combating C. difficile – associated disease. Efforts to combat BI/NAP1 should include good antimicrobial stewardship in addition to effective infection control and environmental intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salminen, M. K., Rautelin, H., Tynkkynen, S., Poussa, T., Saxelin, M., Valtonen, V., & Jarvinen, A. (2004) · Clinical Infectious Diseases · doi:10.1086/380455 · Cited by 426
Invasive Saccharomyces Infection: A Comprehensive Review
Enache-Angoulvant, A., & Hennequin, C. (2005) · Clinical Infectious Diseases · doi:10.1086/497832 · Cited by 369 · cited 1×
“boulardii.(72) To this end, probiotics at this juncture are not recommended at our institution.”
Background
Cited by
Antimicrobial‐Associated Risk Factors for Clostridium difficile Infection
Owens, Jr., Donskey, C. J., Gaynes, R. P., Loo, V. G., & Muto, C. A. (2008) · Clinical Infectious Diseases · doi:10.1086/521859 · Cited by 603
Narrative Review: The New Epidemic of Clostridium difficile–Associated Enteric Disease
Bartlett, J. G. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00008 · Cited by 599
Measures to Control and Prevent Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521861 · Cited by 311
Treatment of Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521860 · Cited by 287
Lewis, B. B., Buffie, C. G., Carter, R. A., Leiner, I., Toussaint, N. C., Miller, L. C., Gobourne, A., Ling, L., & Pamer, E. G. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv256 · Cited by 197
“nerable patient populations has led to the consideration of using metronidazole or vancomycin prophylactically [15, 26].”
Background
Metadata
- Authors
- Owens, R. C.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2006-03
- Volume
- 26
- Issue
- 3
- Pages
- 299-311
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1989065644
- Cited by
- 58
- References
- 2
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clostridium difficile–Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists. https://app.cochat.ai/papers/10.1592/phco.26.3.299
- The paper
- Owens, R. C. (2006). Clostridium difficile–Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.26.3.299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.